Bio Pharma Innovation Trend

Bio Pharma Innovation Trend analyzes comprehensive data source texts for scientific articles or news weekly/monthly and uploads keywords and relevant articles.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Jan. 9-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
https://t.co/SoFzv3aOgm

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Jan. 9-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases
https://t.co/bYv92lo94F

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
BLA filings for LAD-I and FA on track for Q2 2023 and Q4 2023, respectively
https://t.co/1wGs3SFslF

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Eli Lilly acquisition of Akouos: The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class AAV gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
https://t.co/BcDXS3kMZU

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Nov. 28-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Sarepta Therapeutics: U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
https://t.co/wHuPIKkgxO

[Bio Pharma Innovation Trend @BioPharmaInnov1]

BioMarin Announces Incremental Progress on BLA for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A https://t.co/XL3pay1Nab
Current PDUFA Date of March 31, 2023, Could Be Extended by 3 Months, If 3-Year Data Submission Deemed a Major Amendment

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Nov. 7-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
https://t.co/2npDGUvFWh

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Oct. 31-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
https://t.co/n1gg0VcaRs
First five patients in Ph1/2 trial show systemic gene therapy effect across multiple tissues evaluated

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Oct. 24-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
https://t.co/3DPn1EWhgt
AVR-RD-02 has previously received Fast Track from FDA, orphan drug designation in U.S. and EU, and ILAP designation from the U.K. MHRA

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Syncona to Acquire Applied Genetic Technologies Corporation https://t.co/pYkk8zR3Kr

[Bio Pharma Innovation Trend @BioPharmaInnov1]

FDA Adcomm to Meet on BioMarin's Hemophilia A Gene Therapy | BioSpace https://t.co/yb2tSd8e1g #jobs
FDA plans to hold an advisory committee meeting to discuss the company's gene therapy for hemophilia A.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs
https://t.co/K3Ip6b8oAo
Astellas to receive an exclusive option to obtain an exclusive license for TSHA-102 for Rett syndrome and TSHA-120 for GAN

[Bio Pharma Innovation Trend @BioPharmaInnov1]

FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A https://t.co/4K2Uxu5WY5
The data package includes supportive evidence from five years of follow-up from the 6e13 vg/kg dose cohort.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

30 keywords from #biotech #pharma news about #genetherapy last week (Oct. 10-) using #NLP #textanalytics
Key news for each keyword follows in this thread.

[Bio Pharma Innovation Trend @BioPharmaInnov1]

Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper | BioSpace https://t.co/9TJWMkbdpa #jobs
The error was in a Kaplan–Meier curve that represented the survival of mice with spinal muscular atrophy that received either Zolgensma or a control scAAV9-GFP vector.